|
2017 Conference Publication Alemtuzumab demonstrated durable efficacy and safety in CARE-MS I patients switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study)Oreja-Guevara, C., Alroughani, R., Brassat, D., Boyko, A. N., McCombe, P., Steingo, B., Van Wijmeersch, B., Margolin, D. H., Daizadeh, N., Rodriguez, C. E. and Vermersch, P. (2017). Alemtuzumab demonstrated durable efficacy and safety in CARE-MS I patients switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study). 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731406 |
|
2017 Conference Publication Pregnancy incidence, therapy exposure and post-partum relapse risk: a 12-year retrospective multicentre analysisJokubaitis, Vilija, Ai-Lan Nguyen,, Kalincik, Tomas, van der Walt, Anneke, Lechner-Scott, Jeannette, Barnett, Michael, McCombe, Pamela, Vucic, Steve, Hodgkinson, Suzanne, Slee, Mark, Skibina, Olga, Shaw, Cameron and Butzkueven, Helmut (2017). Pregnancy incidence, therapy exposure and post-partum relapse risk: a 12-year retrospective multicentre analysis. Progress in MS Research Conference, Sydney, Australia, 11-13 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517734699 |
|
2017 Conference Publication Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: frequency of abnormality and effect on survivalXu, Zhouwei, Alruwaili, Ashwag, Henderson, Robert and McCombe, Pamela (2017). Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: frequency of abnormality and effect on survival. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, QLD, Australia, 9-12 May 2017. London, United Kingdom: BMJ Group. doi: 10.1136/jnnp-2017-316074.29 |
|
2017 Conference Publication Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosisKalincik, T., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Lechner-Scott, J., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Solaro, C., Grand'Maison, F., Hupperts, R., Prevost, J., Sola, P., Ferraro, D., Terzi, M., Butler, E., Slee, M., Kermode, A., Fabis-Pedrini, M., McCombe, P., Barnett, M., Shaw, C., Hodgkinson, S. and Butzkueven, H. (2017). Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731406 |
|
2017 Conference Publication Risk of secondary progressive multiple sclerosis: a longitudinal studyFambiatos, A., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Prat, A., Girard, M., Duquette, P., Lugaresi, A., Izquierdo, G., Grand'Maison, F., Grammond, P., Sola, P., Ferraro, D., Alroughani, R., Terzi, M., Hupperts, R., Boz, C., Lechner-Scott, J., Pucci, E., Bergamaschi, R., Van Pesch, V., Ozakbas, S., Granella, F., Ramo, C., Turkoglu, R., Iuliano, G., Spitaleri, D. ... Kalincik, T. (2017). Risk of secondary progressive multiple sclerosis: a longitudinal study. 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. |
|
2017 Conference Publication Hypermetabolism in Motor Neurone Disease Is Associated with a Greater Functional Decline But Not Weight LossIoannides, Zara A., Ngo, Shyuan T., Henderson, Robert D., McCombe, Pamela A. and Steyn, Frederik J. (2017). Hypermetabolism in Motor Neurone Disease Is Associated with a Greater Functional Decline But Not Weight Loss. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, May 09-12, 2017. LONDON: BMJ PUBLISHING GROUP. doi: 10.1136/jnnp-2017-316074.18 |
|
2017 Conference Publication Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal studyKalincik, T., Spelman, T., Jokubaitis, V., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Lugaresi, A., Grammond, P., Alroughani, R., Lechner-Scott, J., Prevost, J., Terzi, M., Grand'Maison, F., Boz, C., Trojano, M., Van Wijmeersch, B., Pucci, E., Granella, F., Turkoglu, R., Sola, P., Ferraro, D., McCombe, P., Solaro, C., Van Pesch, V., Ozakbas, S., Slee, M. ... Butzkueven, H. (2017). Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731404 |
|
2017 Conference Publication The risk of overestimating fatness in motor neurone disease: longitudinal assessments of body compositionIoannides, Zara A., Steyn, Frederik J., Henderson, Robert D., McCombe, Pamela A. and Ngo, Shyuan T. (2017). The risk of overestimating fatness in motor neurone disease: longitudinal assessments of body composition. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, 9-12 May 2017. London, United Kingdom: B M J Group. doi: 10.1136/jnnp-2017-316074.35 |
|
2017 Conference Publication Alemtuzumab durably improves clinical outcomes in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS-I patients (TOPAZ study)Coles, A. J., Boyko, A. N., De Seze, J., Hartung, H-P., Havrdova, E., Inshasi, J. S., McCombe, P., Montalban, X., Pozzilli, C., Selmaj, K. W., Vermersch, P., Margolin, D. H., Daizadeh, N., Rodriguez, C. E. and Van Wijmeersch, B. (2017). Alemtuzumab durably improves clinical outcomes in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS-I patients (TOPAZ study). 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731406 |
|
2017 Conference Publication The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosisBrown, J. W. L., Coles, A., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Prat, A., Girard, M., Hupperts, R., Van Pesch, V., Ferraro, D., Alroughani, R., Bergamaschi, R., Pucci, E., Iuliano, G., Lechner-Scott, J., Spelman, T., Jokubaitis, V., Ramo-Tello, C., Spitaleri, D., Granella, F., Solaro, C., Ampapa, R., Deri, N., McCombe, P., Petersen, T., Van Wijmeersch, B., Prevost, J., Sanchez-Menoyo, J. L. ... Robsertson, N. (2017). The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731283 |
|
2017 Conference Publication Pregnancy outcomes in patients with RRMS treated with alemtuzumab from the clinical development programRog, D., Oh, J., Chambers, C., Hellwig, K., McCombe, P., Otero, S., Margolin, D. H., Daizadeh, N. and Compston, D. A. S. (2017). Pregnancy outcomes in patients with RRMS treated with alemtuzumab from the clinical development program. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731404 |
|
2017 Conference Publication Comparison of Faecal Microbe Diversity Between Motor Neurone Disease (Mnd) and Control ParticipantsSteyn, Frederik J., Restuadi, Restuadi, Ioannides, Zara, Ngo, Shyuan T., McRae, Allan, Wray, Naomi R., Henderson, Robert and McCombe, Pamela (2017). Comparison of Faecal Microbe Diversity Between Motor Neurone Disease (Mnd) and Control Participants. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, 9-12 May 2017. London, United Kingdom: BMJ. doi: 10.1136/jnnp-2017-316074.81 |
|
2017 Conference Publication Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosisMerkel, B., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Sola, P., Ferraro, D., Grammond, P., Hupperts, R., Bergamaschi, R., Alroughani, R., Boz, C., Terzi, M., Pucci, E., Van Pesch, V., Grand'Maison, F., Fernandez-Bolanos, R., Lechner-Scott, J., Spitaleri, D., Shaygannejad, V., Iuliano, G., Granella, F., Solaro, C. ... Kalincik, T. (2017). Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731283 |
|
2016 Conference Publication Pregnancy Outcomes in Patients with RRMS Who Received Alemtuzumab in the Clinical Development ProgramOh, Jiwon, Achiron, Anat, Chambers, Christina, Fox, Edward, McCombe, Pamela, Otero, Susana, Margolin, David, Kasten, Linda and Compston, D. Alastair (2016). Pregnancy Outcomes in Patients with RRMS Who Received Alemtuzumab in the Clinical Development Program. AAN 68th Annual Meeting, Vancouver, Canada, 15 - 21 April 2016. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.86.16_supplement.s24.008 |
|
2016 Conference Publication Prospectively tracking disease course and treatment changes in Neuromyelitis Optica using NMOBase, a global online registryKister, Ilya, Bacon, Tamar, Shaygannejad, Vahid, Hor, Jyh Yung, Alroughani, Raed, Haas, Shannon, Terzi, Murat, Boz, Cavit, Olascoaga, Javier, McCombe, Pamela, Fragoso, Yara, Lugaresi, Alessandra, Sola, Patrizia, Vucic, Steve, Pucci, Eugenio, Al-Harbi, Talal, Sajedi, Seyed Aidin, Rojas, Juan Ignacio, Patrucco, Liliana, Cristiano, Edgardo, Suarez, Jose Alberto, Tsolaki, Magdalini, Taylor, Bruce, Iuliano, Gerardo, Devranis, Paschalis, Marriott, Mark and Butzkueven, Helmut (2016). Prospectively tracking disease course and treatment changes in Neuromyelitis Optica using NMOBase, a global online registry. AAN 68th Annual Meeting, Vancouver, Canada, 15 - 21 April 2016. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.86.16_supplement.p5.307 |
|
2016 Conference Publication Pregnancy Outcomes in Alemtuzumab-Treated Female Patients with Active RRMS in the Clinical Development Program.McCombe, P., Achiron, A., Chambers, C., Fox, E. J., Otero, S., Margolin, D. H., Kasten, L. and Compston, D. A. S. (2016). Pregnancy Outcomes in Alemtuzumab-Treated Female Patients with Active RRMS in the Clinical Development Program.. 8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS), Seoul South Korea, Nov 19-21, 2015. LONDON: SAGE PUBLICATIONS LTD. |
|
2016 Conference Publication Durable Effect of Alemtuzumab on Clinical Outcomes Over 5 years in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Despite Most Patients Not Receiving Treatment for 4 Years: CARE-MS I Extension StudyMcCombe, P. A., Hartung, H-P, Havrdova, E., Selmaj, K. W., Margolin, D. H., Kasten, L. and Compston, D. A. S. (2016). Durable Effect of Alemtuzumab on Clinical Outcomes Over 5 years in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Despite Most Patients Not Receiving Treatment for 4 Years: CARE-MS I Extension Study. 8th Congress of the Pan-Asian-Committee-for-Research-and-Treatment-of-Multiple-Sclerosis (PACTRIMS), Seoul South Korea, Nov 19-21, 2015. LONDON: SAGE PUBLICATIONS LTD. |
|
2016 Conference Publication Pregnancy protects against long-term disability accrual in relapsing-remitting MSJokubaitis, V. G., Kalincik, T., Lorscheider, J., Spelman, T., Horakova, D., Duquette, P., Girard, M., Prat, A., Izquierdo, G., Grammond, P., Pucci, E., Grand'Maison, F., Granella, F., Sola, P., Bergamaschi, R., Iuliano, G., Spitaleri, D., Hodgkinson, S., Olascoaga, J., Verheul, F., McCombe, P., Rozsa, C., Lechner-Scott, J., Terzi, M., Hughes, S., Saladino, M. -L., Lugaresi, A., Trojano, M. and Butzkueven, H. (2016). Pregnancy protects against long-term disability accrual in relapsing-remitting MS. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, Sep 14-17, 2016. LONDON: SAGE PUBLICATIONS LTD. |
|
2016 Conference Publication Australian cladribine experienceKalincik, T., Lizak, N., Jokubaitis, V., Butler, E., Lechner-Scott, J., Slee, M., McCombe, P., Shaw, C., Skibina, O., Vucic, S., Shuey, N., Barnett, M., Parratt, J., Butzkueven, H. and Hodgkinson, S. (2016). Australian cladribine experience. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, Sep 14-17, 2016. LONDON: SAGE PUBLICATIONS LTD. |
|
2016 Conference Publication Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).Coles, A. J., Boyko, A. N., Cohen, J. A., De Seze, J., Fox, E. J., Havrdova, E., Hartung, H. -P., Inshasi, J. S., McCombe, P., Selmaj, K. W., Vermersch, P., Van Wijmeersch, B., Margolin, D. H., Thangavelu, K., Rodriguez, C. E. and Montalban, X. (2016). Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, England, Sep 14-17, 2016. LONDON: SAGE PUBLICATIONS LTD. |
